Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years

Recommendations of the Advisory Committee on Immunization Practices--United States, 2022

Tara C. Anderson, DVM, PhD; Nina B. Masters, PhD; Angela Guo, MPH, MBA; Leah Shepersky, MPH; Andrew J. Leidner, PhD; Grace M. Lee, MD; Camille N. Kotton, MD; Kathleen L. Dooling, MD


Morbidity and Mortality Weekly Report. 2022;71(3):80-84. 

In This Article

Future Research and Monitoring Priorities

CDC will monitor adverse events following RZV immunization through VAERS, the Vaccine Safety Datalink, and observational studies. This is particularly important given the heterogeneity of herpes zoster risk within and across immunocompromised groups and the novel adjuvant and high rates of reactogenicity of the vaccine. Limited data for outcomes deemed important by the work group (e.g., possible graft rejection, graft-versus-host-disease, immune-mediated disease) highlight the need for additional research. Additional post-marketing monitoring will include studies conducted by GSK and reported to FDA. Continued monitoring of the impact of the U.S. varicella and herpes zoster vaccination programs on herpes zoster epidemiology will be important to guide future herpes zoster vaccination recommendations.